Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Expert Video Report on therapeutic advances in NSCLC from 2021 ASCO Annual Meeting

Reporting from 2021 ASCO Annual Meeting, Heather Wakelee comments on promising results from IMPOWER 010 testing atezolizumab vs best standard of care after adjuvant chemotherapy for stage II NSCLC with tumour expressing PD-L1. She also reports the overall survival results and subgroup analysis from the CodeBreaK 100 trial evaluating sotorasib in pretreated KRAS G12C mutated NSCLC, as the drug has just been approved in the US.

This video was supported with an educational grant from Bayer, Daiichi Sankyo and Roche.
The selection of study results covered in this track is exclusively under the responsibility of ESMO and the speakers selected by ESMO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings